Biotech entity
pharma is the sole category represented across all 2 tracked stories. Meiji Seika Pharma is most often covered alongside Arcturus Therapeutics, which appears in 1 of these 2 stories. That works out to roughly 0.1 stories per week across a 176-day span.
Last mentioned: 14h ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 2 tracked stories. Meiji Seika Pharma is most often covered alongside Arcturus Therapeutics, which appears in 1 of these 2 stories. That works out to roughly 0.1 stories per week across a 176-day span. Each story carries 2 original sources on average, compared with 3.5 for the broader beat in this window. At 5.5, the average consequence score sits below the same-window beat average of 6.1. This profile follows 2 Biotech stories mentioning Meiji Seika Pharma across the period from March 2, 2026 to August 24, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 644 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Meiji Seika Pharma. Shared-story counts are live from our verified record — not editorial picks.
Meiji Seika Pharma will transfer manufacturing technology for its Japanese encephalitis vaccine, developed and marketed by KM Biologics in Japan, to Serum Institute of India. SII engineers have already visited Japan, and the Indian firm expects to file for regulatory approval as early as 2027.
Source: news.webindia123.com · aninews.in
Arcturus Therapeutics and Rigel Pharmaceuticals are set to report Q4 2025 results, highlighting a pivotal year for mRNA platform validation and oncology market expansion. Investors are focused on Arcturus's sa-mRNA commercial progress in Japan and Rigel's sales trajectory for its flagship hematology treatments.
Meiji Seika Pharma is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
